MediWound’s NexoBrid® to be Highlighted in Presentations at the American Burn Association 50th Annual Meeting Being Held on April 10-13, 2018 in Chicago

Presentations highlight European consensus around the efficacy and benefits of NexoBrid use in severe burns

YAVNE, Israel, April 09, 2018 -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that six presentations highlighting the positive results achieved by clinicians using NexoBrid^® as an effective enzymatic debridement for severe burns will be presented during the American Burn Association (ABA) 50^th Annual Meeting on April 10-13, 2018 in Chicago, IL.

“We are honored to have physicians share their NexoBrid experience with this prestigious group of global burn and wound specialists,” said Gal Cohen, President and Chief Executive Officer of MediWound. “Data continue to demonstrate the benefits of NexoBrid across many different aspects of burn care, including prompt assessment of burn severity post-NexoBrid eschar removal, treatment of large burns and use in cases of mass casualties. Moreover, at the coming ABA, European burn experts will share with their US peers the European consensus work, which listed 68 different consensus statements regarding the use and benefits of NexoBrid that were voted on by leading burn specialists from prominent burn centers across Europe after accumulating mutual experience in the treatment of over 500 patients.”

The following data highlighting NexoBrid will be presented during the ABA meeting: 

About the American Burn Association
The American Burn Association and its members dedicate their efforts and resources to promoting and supporting burn-related care, prevention, and research. The ABA has more than 2,000 members in the United States, Canada, Europe, Asia, and Latin America. Members include physicians, nurses, occupational and physical therapists, researchers, social workers, firefighters, and hospitals with burn centers. The ABA’s multidisciplinary membership enhances its ability to work toward common goals with other organizations on educational programs.

About MediWound Ltd.
MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid^®, received marketing authorization from the European Medicines Agency as well as the Israeli and Argentinian Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns. NexoBrid^® represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues.

MediWound's second innovative product, EscharEx^® is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. EscharEx^® contains the same proteolytic enzyme technology as NexoBrid^®, and benefits from the wealth of existing development data on NexoBrid^®.  In two Phase 2 studies, EscharEx^® has demonstrated safety and efficacy in the debridement of chronic and other hard-to-heal wounds, within a few daily applications.   For more information, please visit www.mediwound.com. 

Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to the regulatory authorizations and launch dates. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on MediWound’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. In particular, you should consider the risks discussed under the heading “Risk Factors” in our annual report on Form 20-F for the year ended December 31, 2017 and information contained in other documents filed with or furnished to the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. The forward-looking statements made herein speak only as of the date of this announcement and MediWound undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Contacts:
Sharon Malka
Chief Financial and Operations Officer
MediWound Ltd.
[email protected]

Bob Yedid
Managing Director
LifeSci Advisors
646-597-6989
[email protected]